Chronic Pain

Zhittya Genesis Medicine is developing FGF-1 to treat chronic and neuropathic pain at its source — by regenerating injured nerves, calming the neuroinflammation that keeps pain switched on, restoring blood flow to oxygen-starved nerve tissue, and protecting the cellular energy supply that failing neurons depend on. It is a non-opioid candidate designed to modify the disease rather than simply mask the signal.

An estimated 50 million-plus Americans live with chronic pain, and roughly one in five U.S. adults is affected — a rate that now exceeds diabetes, depression, or high blood pressure. The therapies most patients are offered (opioids, NSAIDs, anticonvulsants, antidepressants) act on the perception of pain without addressing the injured tissue that produces it, which is why relief is partial and, with opioids, carries a crisis of dependence.

FGF-1 is one of the most potent known stimulators of angiogenesis, and Zhittya's management has invested over $190 million advancing the molecule through US FDA Phase IIA/IIB clinical trials across multiple indications, with an existing human safety foundation and an intranasal delivery route already in clinical use for neurological conditions. That same platform is mechanistically matched to the biology of chronic pain.

The Science: How FGF-1 Targets Pain

Recent research reframes chronic pain as a self-reinforcing cycle operating at the level of the individual cell: nerve injury and metabolic stress raise reactive oxygen species and disrupt the mitochondria inside sensory neurons, which sensitizes pain-sensing neurons and activates the surrounding glial cells, releasing inflammatory mediators that injure neurons further. The published literature documents FGF-1 acting on every node of that cycle — something no single conventional analgesic does.